Independent information. England-wide.Public data. Clear sources.

NCT06682988

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Registered research study with 3 identifiable England locations. See source dates, location-specific recruitment and the original study record.

Study facts

Conditions recorded
Advanced High-Grade Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancers
Lead sponsor
AbbVie
Study type
Interventional
Overall status
Recruiting · this can differ by location
Age range in the record
18 Years to Not specified
Sex eligibility field
Female
Healthy volunteers accepted
No, according to the record
Phase
Phase2
Study record last updated
26 May 2026
Study team last verified status
2026-05

These fields are a starting point. Eligibility can include diagnosis, treatment history and other criteria shown only in the complete source record. A registry entry does not establish treatment effectiveness.

England study locations

A location is reproduced as named in the study record. A source map point can represent a town; it is not used here as a hospital entrance or to identify a care provider.

Location in the sourceLocal recruitment statusGeographic connection
Addenbrookes Hospital /ID# 272162

Cambridge · CB2 2QQ

RecruitingEngland location

Source location point within ONS England boundary

Royal Devon and Exeter Hospital /ID# 272170

Exeter · EX2 5DW

RecruitingCare in Exeter

England postcode

University College London Hospital /ID# 272115

London · NW1 2BU

RecruitingCare in Camden

England postcode

Questions for the research team

  • Is this exact location currently enrolling participants, and do my circumstances meet the full criteria?
  • What visits, tests, possible risks and follow-up would participation involve?
  • Are travel costs or accessibility arrangements available?
  • How would participation affect my usual care, and what happens if I withdraw?

Source: ClinicalTrials.gov, a United States Government database. Contains OS data © Crown copyright and database right 2026. Contains National Statistics data © Crown copyright and database right 2024; ONS country boundaries (December 2024).

Source processed: 2026-09-10 09:00:04 UTC. Retrieved: 10 September 2026. ClinicalTrials.gov terms.

How we selected and connected these records

Selected registered studies with an overall status of Recruiting or Not yet recruiting and at least one England location established by postcode, recorded nation, or source coordinates within the ONS December 2024 boundary. Retained structured fields; omitted descriptions, eligibility text, contacts and non-England locations. Deduplicated identical locations. Linked local care areas only by exact postcode geography. Location points are used for nation filtering, not directions or facility matching.